Search This Blog

Thursday, April 29, 2021

Pluristem: Positive Phase 1 topline data in hematology study

 

  • New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatments

  • The company will conduct an analyst and investor call on May 3, 2021, at 10am EDT

The company will conduct an analyst and investor call on May 3, 2021, at 10am EDT, for registration: https://Veidan.activetrail.biz/pluristem

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)